Leo Pharma starts phase III hand eczema trial

Leo Pharma will test the effectivity of its treatment delgocitinib in treating chronic hand eczema in a phase III trial. It has high hopes for the indication.

Photo: Leo Pharma / PR

After a positive phase II study, Leo Pharma has moved onto phase III trials for its eczema treatment delgocitinib. The first patients have been enrolled in the trial.

Delgocitinib is under development as a treatment for chronic hand eczema, which is eczema on the hands that lasts longer than three months or appears more than twice a year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs